Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation.
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases. Our precision nanomedicines are selectively taken up only by inflamed tissues, allowing us to treat disease with unprecedented precision.
We have designed a potent anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and retinal pigment epithelial cells in the eye
Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more
Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies REDWOOD CITY, Calif.,